Biomia

Pangea Bio

This biotechnology company develops small molecule medicines for neurological and neuropsychiatric disorders using an artificial intelligence platform to identify compounds from natural sources.

Pangea Botanica

This company develops medicines for neurological and mental health disorders using an artificial intelligence platform to discover neuroactive molecules from medicinal plants.

Syremis

This biopharmaceutical company develops oral small-molecule medicines for patients with schizophrenia, major depressive disorder, and other serious mental health conditions.

Syremis Therapeutics

This biopharmaceutical company develops small-molecule oral medicines for patients with neuropsychiatric conditions, including schizophrenia, major depressive disorder and bipolar depression.

Kasvu Therapeutics

This company develops small-molecule neuroplastogen treatments for neuropsychiatric and neurodegenerative disorders, targeting patients with major depressive disorder and brain diseases.

Sensorium Therapeutics

This biotech company develops central nervous system therapies for patients with anxiety, epilepsy and neurodegenerative diseases using a machine learning drug discovery platform.

Neumora Therapeutics

This biopharmaceutical company develops medicines for patients with neuropsychiatric disorders and neurodegenerative diseases.

MeOmics

The company develops a precision psychiatry platform using patient-derived stem cells and AI to help drug developers accelerate psychiatric medicine discovery.